
Abingworth recruits Chu as partner
Life sciences investor Abingworth has added Shelley Chu to its partner roster three months after reshuffling its senior management team.
Chu will work out of Abingworth's offices in Menlo Park, California. As a partner, she will oversee deal sourcing and execution regarding healthcare assets for the firm.
Her hire sees her leave the corporate ranks after being employed by therapy developer Gilead Sciences, where she held business development responsibilities within the oncology, immunotherapy and hepatitis B areas.
Prior to Gilead, she was consultant at McKinsey and worked for VCs Flagship Ventures and Frazier Healthcare Ventures – she was principal at the latter.
The entrance of a new partner to Abingworth takes place three months after the firm replaced its executive team. The reshuffle, announced in early July, saw Tim Haines and Kurt von Emster jointly raised to managing partners following the stepdown of Stephen Bunting, who had held the role since 2002.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater